Proportions and absolute number of CD20+ ALL cases
| CD20+ . | N . | All with MRD . | Low risk . | Medium risk . | High risk . | TEL/AML1 . | Non-TEL/AML1 . |
|---|---|---|---|---|---|---|---|
| BM day 0 | 159 | 45%; 71/159 (52%; 14/27)* | 51%; 18/35 | 38%; 38/100 | 63%; 15/24 | 28%; 13/46 | 51%; 58/113 |
| PB day 0 | 138 | 52%; 72/138 (56%; 14/25)* | 55%; 18/33 | 48%; 42/88 | 71%; 12/17 | 24%; 8/34 | 62%; 64/104 |
| PB day 8 | 138 | 75%; 104/138 (79%; 19/24)* | 76%; 25/33 | 73%; 64/88 | 88%; 15/17 | 56%; 19/34 | 82%; 85/104 |
| BM day 15 | 159 | 71%; 113/159 (76%; 19/25)* | 66%; 23/35 | 70%; 70/100 | 83%; 20/24 | 46%; 21/46 | 81%; 92/113 |
| BM day 33 | 27 | 81%; 22/27 | 100%; 1/1 | 79%; 11/14 | 83%; 10/12 | 0%; 0/1 | 85%; 22/26 |
| CD20+ . | N . | All with MRD . | Low risk . | Medium risk . | High risk . | TEL/AML1 . | Non-TEL/AML1 . |
|---|---|---|---|---|---|---|---|
| BM day 0 | 159 | 45%; 71/159 (52%; 14/27)* | 51%; 18/35 | 38%; 38/100 | 63%; 15/24 | 28%; 13/46 | 51%; 58/113 |
| PB day 0 | 138 | 52%; 72/138 (56%; 14/25)* | 55%; 18/33 | 48%; 42/88 | 71%; 12/17 | 24%; 8/34 | 62%; 64/104 |
| PB day 8 | 138 | 75%; 104/138 (79%; 19/24)* | 76%; 25/33 | 73%; 64/88 | 88%; 15/17 | 56%; 19/34 | 82%; 85/104 |
| BM day 15 | 159 | 71%; 113/159 (76%; 19/25)* | 66%; 23/35 | 70%; 70/100 | 83%; 20/24 | 46%; 21/46 | 81%; 92/113 |
| BM day 33 | 27 | 81%; 22/27 | 100%; 1/1 | 79%; 11/14 | 83%; 10/12 | 0%; 0/1 | 85%; 22/26 |
Results from patients that could be analyzed also at day 33.